Cookies?
Library Header Image
LSE Research Online LSE Library Services

An EU-wide approach to HTA: an irrelevant development or an opportunity not to be missed?

Kanavos, Panos, Angelis, Aris and Drummond, Michael (2019) An EU-wide approach to HTA: an irrelevant development or an opportunity not to be missed? European Journal of Health Economics, 20 (3). pp. 329-332. ISSN 1618-7598

Full text not available from this repository.

Identification Number: 10.1007/s10198-019-01037-2

Abstract

An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness assessment (REA) for pharmaceuticals and medical devices. This cooperation is operationalised through a proposal for a regulation. While a good step in the right direction, this HTA cooperation framework needs to be more explicit and pragmatic about clinical value definition, what constitutes quality of evidence, how real-world evidence is handled, whether the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard consistency in REA interpretation. If demand-rather than supply-driven, this initiative can deliver wider benefits: Europe can improve its power in global drug design and development, while Member States will have at their disposal more resources to assess performance of interventions in their healthcare systems.

Item Type: Article
Additional Information: © 2019 the Authors
Divisions: Health Policy
LSE Health
LSE
Subjects: R Medicine > RS Pharmacy and materia medica
Date Deposited: 15 Mar 2019 09:30
Last Modified: 21 Oct 2019 23:16
URI: http://eprints.lse.ac.uk/id/eprint/100252

Actions (login required)

View Item View Item